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Abstract
Background: Previously we reported that the variable outer membrane lipoprotein Vsp1 from the relapsing fever spirochete
Borrelia turicatae disseminates from blood to brain better than the closely related Vsp2 [1]. Here we studied the interaction
between Vsp1 and Vsp2 with brain endothelium in more detail.
Methodology/Principal Findings: We compared Vsp1 to Vsp2 using human brain microvascular endothelial cell (HBMEC)
association assays with aminoacid radiolabeled Vsp-expressing clones of recombinant Borrelia burgdorferi and lanthanide-
labeled purified lipidated Vsp1 (LVsp1) and Vsp2 (LVsp2) and inoculations of the lanthanide-labeled proteins into mice. The
results showed that heterologous expression of LVsp1 or LVsp2 in B. burgdorferi increased its association with HBMEC to a
similar degree. Purified lanthanide-labeled lipidated Vsp1 (LVsp1) and LVsp2 by themselves were capable of associating with
HBMEC. The association of LVsp1 with brain endothelium was time-dependent, saturable, and required the lipidation. The
association of Vsp1 with HBMEC was inhibited by incubation at lower temperature or with excess unlabeled LVsp1 or LVsp2
but not with excess rVsp1 or mouse albumin or an anti Vsp1 monoclonal antibody. The association of LVsp2 with HBMEC
and its movement from blood to brain parenchyma significantly increased in the presence of LVsp1.
Conclusions/Significance: Variable bacterial outer membrane lipoproteins interact with brain endothelium differently; the
lipidation and variable features at the protein dome region are key modulators of this interaction.
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Introduction
Little is known about the interaction of bacterial lipoproteins
with brain endothelium. Previous studies in our laboratory with
the relapsing fever (RF) spirochete Borrelia turicatae (Bt) have shown
that isogenic serotypes expressing different variable outer mem-
brane lipoproteins vary in their localization in vivo: serotype 1
(Bt1), defined by expression of Variable small protein 1 (Vsp1),
infects and inflames the brain better than isogenic serotype 2 (Bt2),
defined by expression of Vsp2; conversely, Bt2 causes higher peak
bacteremia and systemic disease than Bt1 [2–9]. In recent
experiments using lanthanide-labeled purified lipidated Vsp1
and Vsp2 we showed that LVsp1 disseminates to and inflames
the brain better than Vsp2 [1]. This same study showed that co-
administration with LVsp2 displaced LVsp1 away from the brain
parenchyma into brain capillaries [1].
The underlying mechanism explaining the greater ability of
Vsp1 to move to the brain from the periphery remains to be
determined. One possibility is that Vsp1 binds to brain endothelial
cells better than Vsp2. Another possibility is that LVsp1 may be
internalized and transported through brain endothelial cells better
than LVsp2. Previously we observed by immunofluorescence
microscopy that LVsp1 released from Bt1 can be internalized into
human brain microvascular endothelial cells (HBMEC) [10]. Here
we studied the interaction between Vsp1 and Vsp2 with brain
endothelium using cell association assays with radiolabeled
recombinant Borrelia burgdorferi transformants displaying LVsp1 or
LVsp2 in their surface, radiolabeled sonicated proteins from Bt1,
and lanthanide-labeled purified LVsp1 and LVsp2 present alone
or in combination in vitro and in vivo. The results revealed that
LVsp1 and LVsp2 by themselves associate with brain endothelial
cells to similar degree and suggest that the ability of Vsp1 to
disseminate to the brain is determined by greater ability of Vsp1 to
traffic across endothelial cells into the brain parenchyma. Almost
as important was the finding that the presence of Vsp1 enhances
the ability of Vsp2 to cross the blood-brain barrier.
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Association of Vsp-expressing B. burgdorferi with human
eukaryotic cells
We began this study by measuring the association of Vsp-
recombinant B. burgdorferi with different human eukaryotic cells.
First we used a high passage, non-infectious B313 strain of B.
burgdorferi that had been previously genetically modified to express
Vsp1 or Vsp2 of B. turicatae [11] to assess the effect of heterologous
expression of either Vsp1 or Vsp2 on the association with different
human eukaryotic cells. For this we selected SV-40 transformed
human brain microvascular endothelial cells (HBMEC), IMR90
fibroblasts, and F5 arachnoidal cells derived from a human
meningioma [10]. We compared the association of wild type and
Vsp-recombinant clones of B313 with the 3 eukaryotic cells using
12 mm collagen-coated transwell chambers with confluent
monolayers grown on polycarbonate membranes as before [10].
We verified that the confluent monolayers formed a physical
barrier to different degree: HBMEC restricted the movement of
2000 dextran blue into the lower chamber to the highest degree
(Figure 1A). Collagen-coated polycarbonate inserts without the
monolayers did not restrict the movement of either Vsp1 or Vsp2-
recombinant B313 (Figure 1B). This was important because B.
burgdorferi can interact with collagen [12] and because the HBMEC
culture medium contains heparin, which is bound by Vsp2 but not
by Vsp1 [13]. To compare the association of Vsp-expressing
recombinant B313 cells with the eukaryotic cells monolayers we
inoculated motile borrelias that had metabolically labeled with
S
35-amino acids into the upper transwell chamber and measured
the radioactivity in the lower chamber 4 h later. The results
showed that confluent monolayers of HBMEC severely restricted
the movement of both Vsp1 and Vsp2-expressing B. burgdorferi
transformants (Figure 1C). A similar, albeit less pronounced,
restriction of movement into the lower chamber was observed for
B313-Vsp2 with IMR90 and F5 monolayers (Figure 1C). We
concluded that Vsp1-expressing B313 cells moved better across
IMR and F5 monolayers than if Vsp2 is expressed. Only HBMEC
monolayers severely restricted the movement of Vsp1-B313 into
the lower chamber.
Surface display of Vsp’s increases the association of B.
burgdorferi cells with HBMEC
Next we compared the association of metabolically-labeled wild
type or Vsp-recombinant B. burgdorferi B313 by directly measuring
the radioactivity associated with HBMEC monolayers 4 h after
inoculation into the upper transwell chambers. The results showed
that both Vsp1 and Vsp2-recombinants bound to the HBMEC
monolayers significantly more than the non-recombinant parent
clone (Figure 2A). Since B313 is a non-infectious high passage
strain that lacks linear and circular plasmids encoding important
outer membrane proteins possibly involved in the interaction of B.
burgdorferi with eukaryotic cells (Table 1), we wanted to confirm
these results using Vsp’s expressed in low passage, non-infectious
background. For this we generated Vsp-expressing recombinant B.
burgdorferi cells in the B31-5ANP1 background using two different
clones, B31-5A18NP1 and B31-5A4NP1 that only lack plasmids
lp28-4 and lp56 [14] (Table 1). The vsp1 and vsp2 genes were
introduced using pBSV2.2, a modified pBSV2 shuttle vector
containing a gentamicin resistance marker. Identical to the high
passage B313 recombinants [11], the expression of Vsp1 and Vsp2
was driven by the constitutive flagellar promoter PflaB. Western
immunoblots with monoclonal antibodies to Vsp1 and Vsp2
confirmed expression of the respective Vsp protein in all clones
tested (Figure 3). The recombinant Vsp’s were shown to be surface
Figure 1. Movement of non-infectious Vsp-expressing Borrelia
burgdorferi across eukaryotic cell monolayers. (A) Movement of
2000 dextran blue across confluent monolayers of human brain
microvascular endothelial cells (HBMEC), human fibroblast cells
(IMR90), and human arachnoidal cells (F5) compared with collagen-
coated inserts alone (without cells); notice that all monolayers
significantly limited the movement of 2000 dextran blue from the
upper to the lower transwell chamber. (B) Movement of wild type
(B313) and Vsp1 (B313-Vsp1) or Vsp2-(B313-Vsp2) transformants of non-
infectious high passage B. burgdorferi B313 clones across collagen-
coated inserts without cells; notice their similar movement into the
lower chamber. (C) Movement of S35-radiolabeled B313-Vsp1 and
B313-Vsp2 transformant clones across fibroblast (IMR), arachnoidal (F5),
and brain microvascular endothelial cell (HBMEC) monolayers. Notice
that only HBMEC severely limited the movement of both Vsp-
recombinant B. burgdorferi transformants into the lower chamber. All
experiments represent data from 3–4 transwells and were repeated at
least twice for consistency.
doi:10.1371/journal.pone.0013257.g001
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K (Figure 3). Vsp-expressing transformants lost only cp9 and cp32-
8 (Table 1) and retained infectivity for SCID mice (not shown).
Radiolabeled wild type and Vsp-transformant clones of B31-
5A18NP1 were compared for their ability to associate with
HBMEC monolayers using the transwell assay as before. The
results again showed that the Vsp-transformants associated with
HBMEC much more than the wild type (Figure 2B). The
association with HBMEC was lower in the low passage, infectious
B31-5A18NP1 background compared to the high passage, non-
infectious B313 background (Figure 2). We concluded that
expression of either Vsp1 or Vsp2 increased the association of B.
burgdorferi with HBMEC to similar degree and that the infectious
background strain showed half the association with HBMEC than
the non-infectious background strain.
Strength of the association of Vsp-transformants of B.
burgdorferi with HBMEC
Next we investigated the strength of the association of Vsp-
expressing transformants of B31-5A18NP1 with HBMEC. For this
metabolically labeled motile spirochetes were added to confluent
HBMEC monolayers in 96 well plates for 4 h at 37uC. The
supernatant was collected to measure unbound radioactivity while
the monolayers were gently rinsed in media. To measure the
strength of the association we first incubated the HBMEC
monolayers with 250 nM NaCl in PBS for 10 minutes and
harvested the supernatant to measure its radioactivity. Next we
incubated the HBMEC monolayers with 0.5% SDS in ddH20 for
10 minutes and harvested the resultant cell lysates to also measure
its radioactivity. The data was analyzed as ratios of bound to
unbound radioactivity in the 250 nM NaCl wash and in the lysate.
The results showed that both the 250 nM NaCl wash and the lysis
released radioactivity to a higher degree with the Vsp-transfor-
mants than with the wild type strain (Figure 4A). We also
examined the effect of incubation at lower temperature on the
association of metabolically labeled B31-5A18NP1-Vsp1 with
HBMEC. The results showed that the observed association was
significantly lowered by incubation at 4uC compared to 37uC
(Figure 4B).
Vsp1 antagonism does not interfere with the association
of Bt1 with HBMEC
Since we had been studying the association of Vsp-transfor-
mants with HBMEC monolayers by measuring the signal from
S35-radiolabeled aminoacids, it was possible that the observed
association corresponded to the binding and/intracellular move-
ment of proteins rather than whole spirochetes. To begin
investigating this possibility we incubated HBMEC monolayers
in transwell chambers with metabolically labeled Bt1 spirochetes
that had been sonicated to release proteins into solution. The
results showed that sonication did not prevent the association of
Figure 2. Binding of Vsp-recombinants of Borrelia burgdorferi to
human brain endothelium. Metabolically labeled wild type or
Vsprecombinant high passage non-infectious (panel A) or low passage
infectious (panel B) B. burgdorferi were incubated with human brain
microvascular endothelial cell (HBMEC) monolayers. Binding to HBMEC
monolayers was measured in transwell chambers 4–5 hours after
inoculation into the upper chamber with S35-aminoacid labeled motile
spirochetes. All experiments were repeated at least twice and with 3–4
transwells per borrelia. Notice significantly higher percentage of
radioactivity in the HBMEC monolayer of transwell chambers inoculated
with either Vsp1 or Vsp2-recombinant clones compared to wild type B.
burgdorferi. Also notice that association with HBMEC is higher in the
high passage non-infectious background (panel A).
doi:10.1371/journal.pone.0013257.g002
Table 1. Strains used in this study.
Name Description Mouse infectivity Missing plasmids
a References
B313 B313 pBSV2 Non-infectious cp9, cp32-4 to -9, lp21, lp25, lp28-1 to -4, lp36, lp38,
lp54, lp56
[11]
B313-Vsp1 B313 pBSV2.vsp1 Non-infectious cp9, cp32-4 to -9, lp21, lp25, lp28-1 to -4, lp36, lp38,
lp54, lp56
[11]
B313-Vsp2 B313 pBSV2.vsp2 Non-infectious cp9, cp32-4 to -9, lp21, lp25, lp28-1 to -4, lp36, lp38,
lp54, lp56
[11]
B31-5A18NP1 DBBE02 Infectious lp28-4, lp56 [14]
B31-5A18NP1-Vsp1 B31-5A18NP1 pCRW1 clone #4 Infectious cp9, cp32-8, lp28-4, lp56 This study
B31-5A18NP1-Vsp2 B31-5A18NP1 pCRW2 clone #4 Infectious cp9, cp32-8, lp28-4, lp56 This study
aPlasmids lost in transformants are underlined.
doi:10.1371/journal.pone.0013257.t001
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Since Vsp1 is the most abundant protein of Bt1 spirochetes
[5,15,16], next we studied whether Vsp1 antagonism may interfere
with the observed association. For this we incubated sonicated
S35-radiolabeled Bt1 spirochetes with HBMEC monolayers with
or without previous pre-incubation for 1 h with 1 mg/ml of IgG3
monoclonal antibody 1H12 that binds to the membrane-distal
variable regions 1 and 3 of the Vsp1 dome (O. Kumru and W.
Zu ¨ckert, unpublished results). We also included the Fab fragment
of 1H12 to control for possible effects of the Fc fragment of 1H12
on the association [17]. The results showed that pre-incubation
with either the whole IgG or the Fab fragment of 1H12 did not
reduce the association of sonicated Bt1 proteins with HBMEC
(Figure 5). Compared to the Fab fragment, pre-incubation with
whole 1H12 IgG increased the association of sonicated Bt1
proteins with HBMEC, suggesting Fc-mediated increased associ-
ation of Vsp1 with HBMEC.
Association of Vsp1 with HBMEC
Next we studied whether Vsp1 by itself is capable of associating
with HBMEC. For this it was necessary to first isolate, purify, and
label Vsp1. Wild type lipidated Vsp1 (LVsp1) was isolated from
cultured Bt1 spirochetes by OGP detergent extraction. We
similarly purified wild type lipidated Vsp2 (LVsp2) from cultured
Bt2 spirochetes since the Vsp2 dome is so different from the Vsp1
dome [18]. To investigate the possible role of the lipidation we
used a recombinant non-lipidated Vsp1 that had been previously
prepared in E. coli [11]. Mouse albumin, a protein abundant in the
blood was selected as the non-specific control. The purity of the
protein preparations was examined by Coomassie blue staining
SDS-PAGE (Figure S1). To label the proteins we selected the
lanthanide Europium (Eu)-DTTA, a time-resolved fluorescence
(TRF) tag that exhibits high sensitivity and stability when bound to
proteins [1,19,20]. Extensive testing demonstrated the purity and
stability of the Eu-labeled proteins (see methods and Figures S1
and S2).
To investigate whether LVsp1 does associate with HBMEC first
we incubated HBMEC in suspension in Eppendorf tubes with Eu-
labeled lipidated Vsp1 (Eu-LVsp1) at different concentrations for
various times. Non-lipidated Eu-rVsp1 and Eu-albumin were
included as controls. A control experiment in which Eu-LVsp1
was added to Eppendorf tubes without HBMEC showed that the
observed association of Eu-LVsp1 with HBMEC was not simply
the result of Eu-LVsp1 binding non-specifically to the Eppendorf
tube (Figure S3).
All experiments used 2 h incubation at 37uC under gentle
rotation with 0.2 mg of each Eu-labeled protein except were
indicated. Following incubation, HBMEC were collected by
centrifugation and the supernatant removed for examination by
TRF. After rinsing in clear media, the HBMEC pellet was lysed by
incubation with enhancing solution followed by sonication and
also examined for TRF. Results were expressed as ratio of counts
per second (cps) of Eu in the lysate relative to Eu in the unbound
Figure 3. SDS-PAGE and Western blot of Vsp1- and Vsp2- expressing recombinant low passage infectious clones of B. burgdorferi
B31. Whole-cell lysates of Vsp1 and Vsp2 recombinant clones of low passage infectious B. burgdorferi B31 were characterized by Coomassie-stained
12% SDS-PAGE (upper panel) and immunoblot with monoclonal antibodies to Vsp1, Vsp2, OspA and FlaB. Borrelia cells were treated (+) or not (2) in
situ with proteinase K for digestion of surface-exposed proteins prior to lysis and SDS-PAGE. Two separate clones (#2 and #4) of two different B.
burgdorferi background strains (B31-5A4NP1 and B31-5A18NP1 (Kawabata et al. 2004) transformed with vsp1 or vsp2 expression plasmids were
analyzed.
doi:10.1371/journal.pone.0013257.g003
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HBMEC in a time dependent manner (Figure 6A&B). They also
showed that the association was saturable since increasing the
amount of input Eu-LVsp1 by 10 fold, from 0.2 to 2 mg, did not
result in higher association (Figure 6A). In contrast, increasing the
amount of HBMEC did increase the association (not shown). The
lipid modification was required for the association since the
association of Eu-rVsp1 was similar to that of Eu-albumin and
media alone and much lower than that of Eu-LVsp1
(Figures 6B&C). Lowering the incubation temperature to 4uC
significantly interfered with the association of Eu-LVsp1 with
HBMEC (Figure 6C).
Vsp1 and Vsp2 interact differently with HBMEC
Next we compared the association of Vsp1 and Vsp2 with
HBMEC. For this we used the same Eppendorf cell suspension
assay as before. The results showed that both proteins showed
similar association with HBMEC: the mean 6 SD ratios of bound
to unbound cps were 2.166(0.93) for Eu-LVsp1 and 2.76(0.4) for
Eu-LVsp2 (p=0.30, Figure 7A&B). We also examined the
mechanism of association of LVsp1 and LVsp2 with HBMEC
using protein competition experiments. First we incubated Eu-
LVsp1 with HBMEC in the presence of 10-fold higher
concentrations of unlabeled LVsp1, rVsp1, or albumin. The
results showed that only excess unlabeled LVsp1 interfered with
the association (Figure 7A). Next we did the same with Eu-LVsp2
by incubating it with 10 times excess unlabeled LVsp2, rVsp2, and
albumin. Unexpectedly, the results showed that none of them
interfered with the association (Figure 7B). Therefore, we
proceeded to study the degree to which excess unlabeled
heterologous Vsp proteins interfered with the association each of
the two Vsp proteins with HBMEC. The results showed that 10-
fold excess unlabeled LVsp2 interfered with the association of Eu-
LVsp1 with HBMEC but that 10-fold excess unlabeled LVsp1 had
the opposite effect: it increased the association of LVsp2 with
HBMEC (Figure 7C).
LVsp1 enhances the movement of LVsp2 across the
blood-brain barrier
Since LVsp1 had increased the association of LVsp2 with
HBMEC next we investigated whether the presence of LVsp1 may
also increase the movement of LVsp2 across the blood-brain
barrier. For this we used mice that had been injected
intraperitoneally with 100 mg/kg of Sm-LVsp1 and 100 mg/kg
of Eu-LVsp2 alone or in combination and necropsied 4 h or
18 hours later [1]. The movement of Eu-LVsp2 from blood to
Figure 4. Stringency of the association of Vsp-recombinant B. burgdorferi clones with human brain endothelium. HBMEC monolayers
on transwell chambers that had been incubated with S35-labeled Vsp-recombinant clones of B. burgdorferi at 37uC and rinsed with media were
washed with 250 mM NaCl PBS followed by lysis with 0.5% SDS in water (panel A). In some experiments we incubated B31-5A18NP1-Vsp1 with
HBMEC also at 4uC (panel B). Results shown the mean 6 SD ratio of counts per minute (cpm) associated with the HBMEC monolayer relative to the
original inoculum (6100) and represent at least two separate experiments using 8 transwell chambers per clone. Notice that both 250 mM NaCl and
0.1% SDS in water released significantly more radioactivity from HBMEC that had been incubated with the Vsp-recombinant clones. Also notice that
the B31-5A18NP1-Vsp1 radioactivity released from HBMEC monolayers by 250 mM NaCl followed by 0.1% SDS decreased by incubation in the cold
(panel B).
doi:10.1371/journal.pone.0013257.g004
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second per microgram of protein of whole brain or brain fraction
(capillary depleted or capillary-enriched) relative to plasma as
before [1]. The results showed that the presence of Sm-L-Vsp1
increased the dissemination of Eu-LVsp2 from blood to the brain
parenchymal fraction in a time dependent manner (Figure 8). We
concluded that LVsp1 enhances the movement of LVsp2 across
the blood-brain barrier.
Discussion
In a previous study we have shown that the RF spirochete Bt1
preferentially associates with HBMEC over fibroblasts or arach-
noidal human cells; this strong association of Bt1 with HBMEC
was shared by isogenic serotypes Bt2 and Bt3 that differ only in the
Vsp protein they express [10]. The same study had suggested that
the observed association could represent the interaction of Vsp1 –
rather than Bt1- with HBMEC as evidenced by the fact that it did
not decrease when Bt1 was heat-killed prior to inoculation into the
upper transwell chamber [10]. In the present study we expanded
the study of the interaction of Vsp1 and Vsp2 with brain
endothelium using a variety of approaches, including: (1)
metabolically labeled Vsp1 and Vsp2 expressing B. burgdorferi
transformants; (2) radiolabeled sonicated Bt1 proteins; (3)
lanthanide-labeled lipidated and non-lipidated Vsp1 and Vsp2.
All experiments in vitro used HBMEC, a human brain endothelial
cell line that has many characteristics of blood-brain barrier
endothelial cells and has proven useful in previous studies with
diverse pathogens, including Escherichia coli [21,22], B. burgdorferi
[23], and B. turicatae [10]. The in vivo studies used mice that had
been injected with lanthanide-labeled proteins as part of a
Figure 5. Vsp1 antagonism does not block the association of
radioactive proteins of B. turicatae serotype 1 (Bt1) with brain
endothelium. HBMEC monolayers on transwell chambers were
incubated for 20 min with sonicated S35-radiolabeled serotype 1 of B.
turicatae that had been incubation for 1 h with or without 1 mg/ml of
anti Vsp1 IgG3 monoclonal antibody 1H12 or its Fab fragment. Notice
that while pre-incubation of Bt1 with the intact monoclonal antibody
increased the association of radiolabeled Bt1 proteins to HBMEC, the
Fab fragment had no effect.
doi:10.1371/journal.pone.0013257.g005
Figure 6. Vsp1 associates with brain endothelium. About
5.5610
5 HBMEC in suspension in Eppendorf tubes under gentle
rotation were incubated with 0.2 mg of Europium-labeled proteins
(unless otherwise indicated) or serum free medium as background
control. After incubation the cells were pelleted by centrifugation,
washed in HBMEC clear media and the supernatant removed to
measure unbound Europium. The cell pellet was lysed in enhancing
solution alone (Panels A&B) or enhancing solution followed by lysis in
Triton X-100 (panel C only) to recover Eu-labeled proteins associated
with the HBMEC. Results are expressed as the mean 6 SD ratio of
counts per second (cps) of Eu-bound to HBMEC relative to unbound Eu
and represent data from at least two separate experiments using 4–6
tubes per protein. Notice that Eu-LVsp1 associated with HBMEC in a
time-dependent manner (panels A–C); also notice that the association
of LVsp1 with HBMEC was saturable (panel A), did not occur with non-
lipidated rVsp1 or albumin (panel B), and decreased by incubation at
lower temperature (panel C).
doi:10.1371/journal.pone.0013257.g006
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the following: (i) Heterologous expression of Vsp1 or Vsp2 increase
the association of B. burgdorferi with HBMEC to similar degree. (ii)
The high passage, non-infectious B313 strain of B. burgdorferi
associates with HBMEC more than the low passage infectious
B31-5A18NP1 strain. (iii) Eu-LVsp1 by itself associates with
HBMEC in a time dependent manner. (iv) The association of Eu-
LVsp1 with HBMEC is saturable, requires the lipidation,
decreases at lower temperature, and is reduced to a similar degree
by excess unlabeled LVsp1 or LVsp2. (v) Pre-incubation with an
antibody specific for the variable dome region of Vsp1 or with
excess unlabeled rVsp1 does not interfere with the association of
Vsp1 with HBMEC. And (vi) LVsp1 increases the association of
LVsp2 with HBMEC in vitro and its movement across the blood-
brain barrier in vivo.
The similarly increased association of B. burgdorferi cells with
HBMEC, independent of whether they express Vsp1 or Vsp2,
indicates that these two members of the Vsp/OspC family of
Borrelia outer membrane lipoproteins [11,24–26] may be brain
endothelial cell adhesins. However, an alternative explanation is
that the increased radioactivity associated with the HBMEC
monolayers is due to increased binding of metabolically labeled
proteins released from the spirochetes rather than due to binding
or cell association of the spirochetes themselves. The findings that
Vsp1 and Vsp2 by themselves are capable of associating with
HBMEC (Figures 6 and 7) and capable of disseminating from
blood to brain in mice ([1] and Figure 8) is supportive of this. It is
possible that this property is shared by other members of the Vsp/
OspC protein family, since association with HBMEC monolayers
has been observed with multiple isogenic serotypes of B. turicatae
[10], isogenic serotypes of B. hermsii [27], and non-Vsp expressing
strains of B. burgdorferi (Figure 2).
The precise mechanism by which the association of Vsp1 with
brain endothelium takes place remains to be determined. Yet,
some important clues are provided by putting our current findings
in the context of previous findings. First, the observed that the
association preferentially occurs with endothelial cells as Vsp1-
expressing B. burgdorferi transformants like their Bt1 counterpart,
associated with HBMEC much more than with fibroblasts or
arachnoidal human cells (Figure 1C). Second, the association does
not require either live or intact bacteria (Figure 5 and [10]), as it
was observed with sonicated proteins from Bt1 and purified Vsp1
and Vsp2. Third, the lipidation is very important for the observed
association (Figures 6–7). Fourth, the observed association does
not appear to simply represent loose extracellular binding since
incubation with higher concentrations of salt and cell lysis released
considerable amounts of protein from HBMEC that had been
already washed (Figure 4). Fifth, the presence of one or more
receptors on the HBMEC membrane is required for the
association because pre-treatment of HBMEC with proteinase K
completely prevents the association [10]. Finally, the finding that
incubation at 4uC lowered the association of both Vsp1-
transformants (Figure 4) and Eu-LVsp1 (Figure 6) with HBMEC
is consistent with protein membrane traffic rather than simple
membrane binding. This is in agreement with the previous
observation by immunofluorescence microscopy that Vsp1
released from Bt1 can be seen intracellularly in HBMEC [10]. It
is well established that when endothelial cells are incubated with
lipoproteins at 4uC, almost all of the receptor-bound ligands
remain on the cell surface [28]; this is commonly referred to as
‘‘cell binding’’. In contrast, when endothelial cells are incubated
with lipoproteins at 37uC both the lipoproteins bound to the cell
surface and receptor-bound ligands are internalized by the cells
[28]; this is referred to as ‘‘cell-association’’. We therefore propose
that the observed association of LVsp1 with HBMEC represents
cell association.
It is very clear that the lipidation plays a critical role in the
association of LVsp1 with HBMEC, although the same does not
appear to be the case for LVsp2 (Figures 6–7). Furthermore, the
finding that unlabeled excess LVsp1 or LVsp2 reduced the
association of Eu-LVsp1 with HBMEC to a similar degree
(Figure 6C) indicates that a specific sequence of the variable dome
region is not critical [18]. This is supported by the observation that
pre-incubation with the anti Vsp1 monoclonal antibody 1H12 did
Figure 7. Lipidated Vsp1 or Vsp2 inhibit the association of LVsp1 with brain endothelium non-specifically. 1610
5 HBMEC in
suspension in Eppendorf tubes were incubated with 0.2 mg of Eu-LVsp1 or Eu-LVsp2 for 2 h at 37uC in the presence or absence of 10-fold excess
unlabeled homologous or heterologous Vsp protein. Results are expressed as the mean 6 SD ratio of counts per second (cps) of Eu associated to
HBMEC relative to unbound Eu and represent data from at least two separate experiments using 8 wells per protein. Notice that the association of Eu-
LVsp1 with HBMEC was blocked by 10-fold excess unlabeled LVsp1 (panel A) or LVsp2 (panel C) but not by 10-fold excess unlabeled rVsp1 or albumin
(panel A). This did not occur for Eu-LVsp2 (Panel B). Also notice that excess unlabeled LVsp1 increased the association of Eu-LVsp2 with HBMEC
(panel C).
doi:10.1371/journal.pone.0013257.g007
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13257Figure 8. LVsp1 increases the movement of LVsp2 from blood to brain parenchyma in mice. The movement of Samarium Eu-LVsp1 (Sm-
LVsp1) and Eu-LVsp2 from blood to brain was studied in groups of 5–6 C57BL10 mice 4 h or 18 h after intraperitoneal inoculation with 100 mg/kg of
each protein alone or together. Results were calculated for whole brain (upper panels), capillary enriched brain fraction (middle panels), or capillary-
depleted brain parenchymal fraction (lower panels). Results are presented as mean 6 SD ratio of counts per second for Sm-LVsp1 or Eu-LVsp2 per
microgram of protein extract from plasma or brain tissue. Notice that the movement of Sm-LVsp1 and Eu-LVsp2 from blood to brain increased
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previously shown that Borrelia lipoproteins can spontaneously
associate with spirochetal membranes and that this is mediated by
the lipidation [29].
What is more difficult to explain is the limited ability of LVsp2
to disseminate from blood to the brain parenchyma relative to
Vsp1 [1]. The binding of LVsp2 to HBMEC is similar to that of
LVsp1 and is not inhibited by LVsp1 (Figure 7). Previous studies
have shown that Vsp2 appears to be more ‘‘sticky’’ than Vsp1, as
shown by its greater binding to extracellular matrix components
like heparin and dermatan sulfate [13]. This same increased
‘‘stickiness’’ to extracellular matrix may explain why the pathogen
load in collagenous tissues like the skin and the heart is much
greater during persistent infection with Bt2 than with Bt1
[2,3,30,31].
It is intriguing that the presence of LVsp1 increased the
association of LVsp2 with HBMEC in vitro (Figure 7) and the
movement of LVsp2 from blood to the brain parenchymal fraction
in mice (Figure 8). Previous studies have shown that Vsp1 and
Vsp2 have protease-resistant, thermostable cores and aggregate as
dimers in solution [32]. If Vsp1 and Vsp2 could form heterodimers
in solution as has been observed with other bacterial proteins [33],
this could explain the enhancing effect that the presence of LVsp1
had on the association of LVsp2 with HBMEC and its traffic
across the blood-brain barrier in mice. LVsp2 has the same
lipidation but is 32% different at the amino acid level from LVsp1
[16,34]; all the differences between LVsp1 and LVsp2 concentrate
in the variable dome region [11,18,32]. Computer modeling of
Vsp2 using the crystal structure of Vsp1 has shown that although
both protein domes are hydrophilic, the Vsp2 dome has many
fewer charged residues. As a result, the dome of Vsp1 is more
polar and its negative electrostatic potential is more pronounced
than that of Vsp2. Such increased polarity of the Vsp1 dome may
facilitate the non-specific binding to electrostatically charged
aminoacid residues on the HBMEC membrane leading to better
cell internalization via adsorptive endocytosis. An endocytic
mechanism has been shown to be used for internalization of E.
coli into HBMEC [22].
Our knowledge of the proteins important for brain infection by
borrelia spirochetes remains rather limited [35–37] compared to
many other pathogenic bacteria [38]. Several spirochetal proteins
that bind to eukaryotic cells and/or tissues have been identified,
including members of the Vsp and Vlp family from RF spirochetes
[13,27], and Osp [39,40], Dbp [41], and VlsE [40] from Lyme
disease spirochetes. On the host’s side, several molecules have
been implicated in the binding of eukaryotic cells and/or the
extracellular matrix to spirochetes, including integrins [42],
glycolipids [43], proteoglycans [41,44], and glycosaminoglycans
(GAGs) [45,46]. There have been several previous studies of the
interaction of borrelia spirochetes with endothelial cells. They
have revealed that borrelias can cross intercellular junctions of
human umbilical vein endothelial cells (HUVEC) [47–50] and
HBMEC monolayers [23]; one study reported that borrelias can
even be internalized into endothelial cells [51]. Several authors
have shown that borrelias can activate endothelium [50,52–58].
One particular observation which is more relevant to the current
study is the demonstration of differential binding of Vsp-expressing
borrelias to glycosaminoglycans (GAG) [11]; this suggests that
Vsp2-expressing spirochetes might get stuck in extracellular matrix
or even on brain endothelium due to their GAG-binding
properties, while Vsp1-expressing ‘teflon’ spirochetes evade that
fate and ultimately get swept into the brain parenchyma.
The observed phenotypic differences between high and low
passage B. burgdorferi background clones might be explained by
their different surface architectures: During extensive passage, the
B. burgdorferi strain derivative B313 lost the majority of its plasmids,
and with it the ability to express many of the strains’ plasmid-
encoded surface proteins such as OspA [32,39]. In this
background, ectopically expressed Vsp proteins are prominently
displayed on the surface without much interference from other
proteins, therefore leading to a pronounced change in phenotype.
In contrast, the low passage B. burgdorferi B31 clone B31-5A18NP1
[14] exhibits a much more complex surface, where multiple
abundant proteins such as Osp’s might at least partially mask the
expressed Vsp proteins and therefore lead to a somewhat
attenuated change in phenotype.
Further work is necessary to characterize the precise mechanism
underlying the observed association of Vsp1 with HBMEC.
Current limitations in deciphering the role of surface lipoproteins
from relapsing fever borrelias in host-pathogen interactions will
also need to be addressed. Studies with primary human brain
endothelial cells might reveal differences to the immortalized
HBMEC cell lines. To conclusively satisfy ‘‘Koch’s molecular
postulates’’ for the biological role of Vsp’s, genetic tools for the
manipulation of B. turicatae need to be developed.
Materials and Methods
Bacterial strains, plasmids, culture, and mouse infectivity
Serotype 1 of B. turicatae has been previously described [5,15].
Since B. turicatae is currently not amenable to genetic manipulation
this precluded us from preparing vsp deletion, i.e. loss-of-function
mutants of B. turicatae. As an alternative we engineered the Lyme
disease spirochete B. burgdorferi to express Vsp1 or Vsp2 in the
outer membrane for gain-of-function experiments. This approach
was used previously to demonstrate the effects of Vsp on the
interaction of spirochetes with glycosaminoglycans [11,13]. All
recombinant B. burgdorferi strains used are cloned derivatives of the
type strain B31 (ATCC 35210). The high-passage non-infectious
B313-based strains were described earlier [11]. In these strains,
vsp1 and vsp2 are encoded on recombinant pBSV2-derived
plasmids [59] and their expression is driven by the constitutive
B. burgdorferi flaB promoter PflaB. The low-passage B. burgdorferi
strains were based on infectious clones B31-5A4NP1 and B31-
5A18NP1 [14]. To introduce vsp1 and vsp2 into these two
kanamycin-resistant background strains, we first modified pBSV2
by replacing its kanamycin (aphI) resistance marker with a
gentamicin resistance (aacC1) marker. The aacC1 gene was
amplified from pKK82 [60] by PCR using thermostable
proofreading Pfx DNA polymerase (Invitrogen, Carlsbad, Calif.)
and primers NdeaacC1-fwd (59- GGAATTCCATATGTTACG-
CAGCAGCAACGA-39) and NcoAataacC1-rev (59-CATGC-
CATGGGACGTCTTAGGTGGCGGTAC-39). The amplicon
was digested with NdeI and AatII and ligated to an NdeI-AatII
pBSV2 backbone fragment, resulting in pBSV2.2. Next, BamHI-
HindIII fragments containing the PflaB-vsp expression cassettes were
excised from pBSV2.vsp1 and pBSV2.vsp2, respectively [11], and
ligated to a BamHI-HindIII-pBSV2.2 backbone fragment, resulting
in plasmids pCRW1 (harboring vsp1) and pCRW2 (harboring
vsp2). B31-5A18NP1 cells were transformed with pCRW1 and
between 4 and 18 h and that Sm-LVsp1 when given alone moved from blood to brain more than Eu-LVsp2, as recently reported [1]. The co-
administration of Eu-LVsp1 with Sm-LVsp1 increased its distribution from blood to the brain parenchymal fraction.
doi:10.1371/journal.pone.0013257.g008
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selected on BSK-II plates containing 200 mg/ml kanamycin and
40 mg/ml gentamicin and multiple independent clones each were
expanded in selective liquid BSK-II [11]. B. burgdorferi plasmid
profiles of background strains and transformants were established
by PCR using plasmid-specific oligonucleotide primers [62,63]. All
clones retained plasmids lp25 and lp28-1, which are essential for
infectivity. Protein lysates from all clones were examined by
Western blot for expression of Vsp 1, Vsp2, OspA, and FlaB with
monoclonal antibodies 1H12, 5F12, H5332, and H9724, respec-
tively [15,64]. The only plasmids lost in some or all of the
transformants were cp9, cp32-8, lp21, lp28-4 and lp56. One clone
each was used for further studies (Table 1). Infectivity was tested
by culturing skin samples from groups of 6–8 mice with severe
combined immunodeficiency (SCID) 2 weeks after intradermal
inoculation with 10
4 B. burgdorferi spirochetes per mouse. Borrelias
were cultured at 34uC in BSK-H medium containing 6% rabbit
serum (Sigma) and counted in a Petroff-Hausser chamber under
phase-contrast microscopy. Recombinant expression of Vsp1 or
Vsp2 was assessed by Western blot with serotype-specific
monoclonal antibodies and rabbit hyperimmune sera against
strain N40 of B. burgdorferi as positive control. For cell incubation
experiments, the bacteria were grown in medium supplemented




as before [10]. At late log phase, cells were pelleted by
centrifugation at 13,000 g for 20 minutes at room temperature,
washed with BSK-H three times to remove unbound radioactivity,
resuspended in fresh BSK-H media with 10% DMSO at a
concentration of 10
8 spirochetes/ml, aliquoted, and stored frozen
at 280uC to be used within two months. Before use, 20% tri-
chloroacetic acid was used to precipitate radiolabeled proteins
from the frozen stocks; we confirmed that $80% of the
radioactivity was protein-bound. Radiolabeled spirochetes were
examined microscopically after thawing to confirm their viability
and only used if .80% were motile.
Eukaryotic cell cultures
HBMEC [21,22], SV40-transformed IMR90 human fibroblasts
[65], and F5 human meningioma/arachnoidal cells [66] were
grown at 37uC in a 5% CO2 atmosphere in media containing 10%
fetal bovine serum. HBMEC media was RPMI1640, 10%
NuSerum, MEM vitamins, MEM non-essential amino acids,
1 mM sodium pyruvate, 2 mM L-glutamine, 30 mg/ml endothe-
lial growth supplement, and 5 U/ml heparin [21,22]. IMR90
media was 1:1 DME/F10; F5 media was RPMI. Preliminary
experiments showed that B. burgdorferi remained viable in
HBMEC, IMR90, and F5 media for up to 24 h while none of
the eukaryotic cell lines grew well in BSK media. Cells were
released from culture flasks by trypsinization, resuspended in fresh
medium, and counted under phase contrast microscopy with a
hemocytometer after mixing with trypan blue to examine viability.
Transwell chamber assays
Two sizes of collagen-coated, 3.0 mm pore membranes for
transwell chambers were used, 12 mm diameter membrane inserts
(Corning Costar 3494) placed in 12-well culture plates (Corning
Costar 3513) for multiple time point sampling and 6.5 mm
diameter membrane inserts (Corning Costar 3496) placed in 24-
well culture plates (Corning Costar 3526) for single time point
sampling. For both transwells 5610
5 eukaryotic cells were seeded
in the upper chambers and allowed to grow to confluency
overnight. For the 12 mm transwells the volumes were 500–600 ml
in the upper chamber and 1,000-1,500 ml in the lower chamber;
20 ml were removed at each time point from both chambers
without replacing the volume. For the 6.5 mm transwells the
volumes were 100 ml in the upper chamber and 600 ml in the
lower chamber. HBMEC were grown to confluency overnight.
Monolayer confluency was examined by adding 50 mg of 2,000
dextran blue (Sigma) in DMEM clear media to the upper transwell
chamber and measuring the optical density in aliquots removed
from the upper and lower chamber by spectrophotometry after
4 h. For experiments with metabolically labeled spirochetes
,5610
4 counts per minute (cpm) of S35-aminoacid labeled
borrelial stocks, corresponding to ,1610
7 spirochetes total, were
added to the upper chamber. In the multiple time point
experiments the radioactivity associated with the monolayer was
measured indirectly using the counts of the original inoculum and
individual 20 mL aliquots from the upper and lower chambers. In
the single time point experiments it was measured directly by
removing the monolayer after rinsing and drying and placing it
into liquid scintillation cocktail (Ecolite). In some experiments S35-
radiolabeled proteins from sonicated Bt1 spirochetes were pre-
incubated for 1 hour at 34uC with ,1 mg/ml of anti Vsp1 IgG3
mouse monoclonal antibody 1H12 [15], its Fab fragments of
1H12 (Pierce Cat# 44985), or media alone as a control prior to
inoculation into the upper transwell chamber. 1H12 binds
specifically to the distal variable region of Vsp1 (W. Zu ¨ckert,
personal communication).
Protein preparation and labeling
Lipidated Vsp1 (LVsp1) and Vsp2 (LVsp2) were prepared from
BSK cultures of serotype 1 (Bt1) or 2 (Bt2) of B. turicatae by
extraction with Octyl b-D-glucopyranoside (OGP) as described
[15]. Both Vsp1 and Vsp2 preparations caused significantly
increased serum levels of IL-10 upon intraperitoneal injection into
mice at 100 mg/kg (not shown), as expected for bacterial
lipoproteins [67]. Further evidence that purified LVsp1 and
LVsp2 were lipidated was that their precipitation in solutions at
concentrations of OGP #0.01%. Mouse albumin was purchased
from Sigma (Cat. No. A1056). Recombinant Vsp1 (rVsp1) and
Vsp2 (rVsp2) are S34-amino terminally truncated non-lipidated
proteins made in Escherichia coli by cloning the vsp1 or vsp2 genes of
B1 or Bt2, respectively [11]. Protein concentration was measured
using the BCA
TM Protein Assay Kit (Pierce Cat No. 23227).
Protein purity was verified by SDS-PAGE (Figure S1A) and their
identification by Western blot with anti Vsp1 (1H12) or Vsp2
(5F12) monoclonal antibodies [15,34] (not shown). Europium (Eu)
labeling of proteins and their purification was performed
according to the manufacturer instructions (Perkin-Elmer, Boston
MA) as described [1]. Briefly, 1 mg of each protein in 50 mM
NaCO3 pH 9.3 was incubated with Europium (Eu) or Samarium
(Sm) labeling reagents (DELFIA labeling Kits) at 25uC in the dark
for 12 hours. Sephadex G-25 chromatography (Sigma 54805) was
used for separation of Eu-labeled protein from free Eu (Figure
S1B). After chromatography the proteins were dialyzed using
Slide-A-Lyzer dialysis Cassette (Pierce Cat No. 66380) against
distilled water at 4uC for 48 hours for further purification (Figure
S1C). After dialysis the Eu-labeled proteins were aliquoted and
stored at 220uC. Trace OGP (#0.01%) was added to the
lipidated proteins to prevent them from precipitating. Immediately
before using them, the proteins were thawed and vortexed for 1 to
2 minutes at 10,000 rpm to bring them into solution.
Stability of Eu-labeled proteins
To verify the stability of the proteins and the lanthanide labeling
we examined aliquots from each of the labeled proteins with the
BCA assay kit (Pierce, Product No. 23337) to measure protein
concentration and with time resolved fluorescence (TRF) to
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continuous storage at 220uC. We confirmed that both the
proteins themselves and the lanthanide-counts were stable for up
to 2 years of continuous storage in the cold (Table S1). We also
confirmed the stability of the Eu-protein binding by measuring the
percentage of Eu-bound to each protein before and after
centrifugation on 8,000 MW centrifugal devices (Amicon Ultra15,
#UFC901008, Millipore, Bedford, MA) that remove free Eu
because of its low molecular weight (,700 dalton) (Figure S2A).
We also verified that the TRF signal was coming from Eu-bound
to protein rather than from free Europium using precipitation with
trichloroacetic acid (TCA) (Figure S2B). For this, an equal volume
of ice-cold 5% TCA was mixed with aliquots of 2 mg of each Eu-
labeled protein diluted in 200 ml of distillated water followed by
centrifugation at 3,000 g for 10 minutes, removal of the
supernatant, and resuspension of the pellet in Delfia enhancing
solution (Perkin-Elmer) by vortexing. Protein-bound Eu was
determined by comparing the cps in the supernatant and the
pellet. We confirmed that the signal was coming from Eu-bound to
protein rather than free Eu by measuring the cps in protein elutes
from bands sectioned from Coomassie-stained 12% SDS-PAGE
gels that had been loaded with aliquots of Eu-labeled proteins. For
this, we excised bands of the predicted size from the acrylamide gel
with a clean razor blade, minced them into smaller pieces, placed
them in a Nanosep centrifugal device with a 10 kDa filter in
elution buffer, used centrifugation at 3,000 g for 20 minutes to
remove free Eu, and measured protein-bound Eu by TRF in
aliquots removed from the upper filter chamber.
Vsp1-HBMEC binding assays
To compare the association of LVsp1 and LVsp2 with
HBMEC we used an assay in which HBMEC were incubated
with the proteins while in suspension on Eppendorf tubes. For
this, 5.5610
5 HBMEC suspended in 0.5 ml of serum free clear
HBMEC medium in 1.5 ml Eppendorf tubes were kept under
gentle rotation and incubated from 10 min to 4 h at 37uC( 4 uC
for some experiments) with 0.2 (2 mg for some experiments) of
Eu-labeled proteins alone or together with 10 times excess (2 mg)
unlabeled proteins. We verified that the tube rotation did not
affect HBMEC viability for up to 2 h using Trypan blue
exclusion (not shown) and that the proteins did not bind non-
specifically to the walls of the Eppendorf tube (Figure S3). After
incubation, HBMEC were harvested by centrifugation at
2,500 rpm (300 g) for 10 minutes and the supernatant examined
for unbound protein by TRF by mixing with Delphia enhancing
solution at 1:20 ratio. The HBMEC pellet was washed 3 times by
gentle resuspension in clear HBMEC medium followed by
centrifugation at 2,500 rpm, lysed by resuspension in 200 mLo f
Delphia enhancing solution (Perkin-Elmer) at room temperature
for 1 h (which also releases the Eu-tag from any protein that was
associated with the cells), ultrasonication in ice for 20 sec, and
centrifugation to pellet cell debris for 25 min in the cold at
13,000 rpm. In some initial experiments an additional lysis in
detergent with Triton X-100 was also used (Figure 7C). Results
were expressed as mean 6 SD ratio of cps bound to unbound to
HBMEC after adjusting for the differences in input volume
(500 mL for the unbound supernatant and 200 mLf o rt h eb o u n d
supernatant).
Vsp dissemination from blood to brain
Groups of 5–7 week old female C3H/HeJ mice were obtained
from Taconic Farms (Germantown, NY) were injected intraper-
itoneally with 100 mg/kg of samarium (Sm)-labeled LVsp1 or/and
Eu-labeled LVsp2 diluted in 200 ml of PBS alone or in
combination; mice injected with PBS alone were used as
background control. Necropsies were done 4 or 18 hours after
protein injection. The movement of Sm-LVsp1 and Eu-LVsp2
from blood to brain was measured as before [1]. After extensive
intracardiac with buffer at necropsy, the brain was removed, one
hemisphere used for whole brain protein extraction and the other
half used for capillary depletion by dextran density centrifugation
[1] to differentiate the protein signal present in brain capillaries
from that present in the brain parenchyma itself.
IL-10 ELISA
Levels of IL-10 were determined using monoclonal antibody
pairs from BD Pharmingen (San Diego, CA) in mouse plasma
12 h after intraperitoneal inoculation of LVsp1, LVsp2, or as
negative control rVsp1; the coating antibody was purified anti-
mouse IL-10 (Cat 551215) and the detection antibody was
biotinylated rat anti-mouse IL-10 (Cat 554423).
Statistical analyses
Comparisons of counts per minute (for radioactivity) or counts
per second (for TRF), either as absolute numbers, percentage of
total counts, or ratios of bound to unbound were done using a one
way (Kruskal-Wallis test with Dunn’s test for multiple compari-
sons) or two-way ANOVA (Bonferroni post-test for multiple
comparisons). Unpaired t-test were used to compare the
movement of proteins from blood to brain/brain fractions when
injected alone or in combination. GraphPad Prism software
version 5.00 for Windows was used for all calculations (GraphPad
Software, San Diego California USA). A p value #0.05 was
considered significant.
Supporting Information
Figure S1 Purification and lanthanide-labeling of Vsp1 and
control proteins. Panel A - Protein preparations were separated on
a 12% SDS-PAGE gel; Coomassie-blue staining revealed only one
band of the expected size for each protein without any
contaminant (lane 2, LVsp1; lane 3, rVsp1, lane 4, albumin).
Notice the absence of the 41kDa flagellin band in all protein
preparations. The molecular weight of the proteins in kDa is
indicated to the left in lane 1. Panel B - Sephadex G-25 gel
chromatography of Eu-labeled LVsp1. The first peak represents
Eu-LVsp1 and the second peak free Eu-chelate. The solid line
illustrates the protein concentration in nmol/L and the dotted line
represents Eu concentration in nmol/L. Similar results were
obtained for Eu-rVsp1 and Eu-albumin (not shown). Panel C -
Time course removal of residual free Eu from Eu-labeled LVsp1
by ddH20 dialysis. The rate of free Eu removal was determined by
measuring Eu concentration on each of 8 fractions of exchanged
water. The data represents mean 6 SD nmol of Eu/L. The dotted
line represents background time-resolved fluorescence.
Found at: doi:10.1371/journal.pone.0013257.s001 (0.65 MB TIF)
Figure S2 Stability of Europium-labeled proteins. We confirmed
the stability of the Eu-protein binding by measuring the
percentage of Eu-bound to each protein before and after
centrifugation on 8,000 MW centrifugal devices that remove free
Eu because of its low molecular weight (,700 dalton) (panel A).
We also verified that the TRF signal was coming from Eu-bound
to protein rather than from free Europium using precipitation with
trichloroacetic acid (TCA) (Panel B).
Found at: doi:10.1371/journal.pone.0013257.s002 (0.27 MB TIF)
Figure S3 Lanthanide-labeled proteins do not bind to the
Eppendorf tubes. We showed by adding Eu-LVsp1 to Eppendorf
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tube itself.
Found at: doi:10.1371/journal.pone.0013257.s003 (1.33 MB TIF)
Table S1 Prolonged storage in the cold does not affect the
concentration of protein or the time-resolved fluorescence of
Europium.
Found at: doi:10.1371/journal.pone.0013257.s004 (0.04 MB
DOC)
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